GLUE

ANALYST NOTE: Monte Rosa Therapeutics, Inc. (GLUE) Date: 2026-06-13 Current Price: $18.31

1. Structural Readiness

State: Context-Only (No actionable technical structure defined in the provided data) Conservative Entry: — Breakout Level: — Extension: — ATR Current: 6.4% (Very High)

Technical Assessment:

2. The Thesis Layer

Primary Secular Thesis: Biotech & GLP-1 → Oncology (Tier Direct) Thesis Strength: High Confidence

Monte Rosa Therapeutics is positioned as a direct beneficiary within the Biotech sector, specifically targeting the intersection of oncology and inflammatory disease through its proprietary protein degradation platform. The company's core thesis relies on the "Biotech & GLP-1" secular theme, with a specific, high-conviction focus on Oncology.

The company is not merely a passive participant but a direct developer of precision medicines designed to degrade therapeutically relevant proteins. The evidence highlights a dual-track approach:

• Oncology: Leveraging MRT-2359 (NEK7 inhibitor) and MRT-8102 (VAV1 MGD) to treat metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular risks associated with inflammation.
• Inflammatory/Immune: Utilizing the NLRP3 inflammasome pathway (via NEK7) for conditions like Crohn's disease and neurodegenerative ailments.

The "Tier Direct" classification reflects the company's role as a primary innovator in this space, rather than a derivative or downstream beneficiary. The high confidence in this thesis is supported by the specific clinical data points released in early 2026, which demonstrate efficacy signals in difficult-to-treat patient subsets (e.g., AR-mutated mCRPC).

3. The Business

Business Model & Industry: Monte Rosa Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, founded in 2019. The company operates in the Healthcare industry, specifically within the Biotechnology sub-sector. Its business model is based on the discovery and development of novel small-molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically-relevant proteins (MGDs).

Key Operations & Pipeline (As of 2026-06-13):

• MRT-2359 (NEK7 Inhibitor): The company has announced positive interim data from a Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide for mCRPC. Specifically, in February 2026, the company reported a 100% PSA response rate in a subset of patients with androgen receptor (AR) mutations (5 out of 5 patients). Management expects to present additional results for the hormone receptor-positive breast cancer cohort in the second half of 2025 (as noted in prior guidance) and plans to initiate a Phase 2 study in combination with a second-generation AR inhibitor in 2026.
• MRT-8102 (VAV1 MGD): In January 2026, the company announced positive interim data from the ongoing Phase 1 study (GFORCE-1). Management anticipates results from this study in the second half of 2026. Furthermore, they plan to initiate a Phase 2 ASCVD study (GFORCE-2) in H2 2026, a Phase 2 study for gout flares (GFORCE-3) in Q4 2026/Q1 2027, and a Phase 2 study for hidradenitis suppurativa (GFORCE-4) in H1 2027.
• Strategic Partnership: Pursuant to a 2024 agreement with Novartis, Monte Rosa granted Novartis an exclusive, royalty-bearing license to develop, manufacture, and commercialize VAV1 MGDs, including MRT-6160, which is in Phase 1 for immune-mediated conditions.
• Pipeline Expansion: The company is also developing programs for CDK2 in ovarian, uterine, and breast cancers, and NEK7 for inflammatory conditions including Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Management expects to submit an IND application for a cyclin E1-directed MGD in 2026.

Financial Position: As of March 31, 2026, the company reported cash, cash equivalents, and marketable securities of $666.2 million. Management stated that these funds are sufficient to fund operating expenses and capital requirements for at least 12 months from the date of the Q1 2026 interim financial statements. However, the company continues to incur losses, reporting a net loss of $44.5 million for the three months ended March 31, 2026, and $38.6 million for the full year ended December 31, 2025.

4. Archetype and Conviction

Archetype: Growth Leader / Clinical Catalyst Valuation Context: The financial spine indicates forward consensus EPS of -1.66 for FY1 and -1.84 for FY2, consistent with a pre-profitability biotech growth company.

Conviction Stack:

• Thesis Strength: High. The company is directly addressing high-unmet-need areas (mCRPC with AR mutations, ASCVD) with a differentiated mechanism of action (protein degradation).
• Evidence Quality: Strong. The evidence base includes specific clinical data (100% PSA response in AR-mutated subset) and clear management guidance on upcoming Phase 2 initiations (GFORCE-2, GFORCE-3) and IND submissions.
• Rerating Potential: High, contingent on the successful initiation and positive readouts of the Phase 2 studies planned for H2 2026 and Q4 2026. The Novartis partnership provides a potential revenue stream and validation of the platform.

Management Expectations (Source: 2026 Filings): Management expects to initiate the Phase 2 ASCVD study (GFORCE-2) in H2 2026 and the Phase 2 gout study (GFORCE-3) in Q4 2026 or Q1 2027. They anticipate results from the GFORCE-1 study in H2 2026. These are the specific milestones management has set for the next 12-18 months.

5. Invalidation, Strengthening, and Gaps

What Would Strengthen the Case:

• Clinical Readouts: Positive top-line data from the GFORCE-1 study (MRT-8102) in H2 2026.
• Trial Initiation: Successful enrollment and initiation of the Phase 2 ASCVD study (GFORCE-2) as planned in H2 2026.
• IND Approval: Receipt of FDA clearance for the cyclin E1-directed MGD IND application in 2026.
• Financial Extension: Evidence that the $666.2M cash runway extends beyond 12 months due to milestone payments or reduced burn, or a successful capital raise at favorable terms.

What Would Invalidate the Case:

• Clinical Failure: Negative or inconclusive results from the GFORCE-1 study or the Phase 2 mCRPC combination study.
• Cash Runway: A significant acceleration in burn rate or inability to raise capital before the 12-month runway expires (post-Q1 2026).
• Regulatory Setback: FDA refusal to accept the IND for the cyclin E1 program or a halt in clinical trials.

Gaps in the Evidence Base:

• Technical Structure: There is no data on price action, volume, or support/resistance levels to determine a technical entry or stop. The "Context-Only" state is a significant gap for a technical analysis framework.
• Revenue Visibility: While the Novartis deal exists, specific milestone payment amounts or royalty rates are not detailed in the provided evidence, leaving the near-term revenue profile uncertain.
• Competitive Landscape: The evidence does not detail the competitive positioning of MRT-2359 or MRT-8102 against other emerging therapies in the mCRPC or ASCVD spaces.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: 100% PSA response rate in AR-mutated mCRPC subset (5/5 patients); $666.2M cash runway covering 12+ months; Novartis partnership for VAV1 MGDs. Key risks: Very high ATR (6.4%) indicating extreme volatility; binary clinical outcomes in Phase 2 trials; continued negative cash flow and net losses. Sizing hint: Position size must be reduced to account for binary clinical risk and lack of technical structure; treat as a high-conviction binary event rather than a trend trade. Expected path: Management expects to initiate Phase 2 ASCVD and gout studies in H2 2026/Q4 2026; stock likely to remain volatile until GFORCE-1 data readout in H2 2026. Expected horizon: 6 to 12 months (aligned with GFORCE-1 data readout and Phase 2 initiation). Failure mode to watch: Negative interim data from GFORCE-1 study or a cash runway extension failure requiring dilutive financing.